2018-2023 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Report (Status and Outlook)

August 2018 | 117 pages | ID: 21F63447426EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Gastroesophageal Reflux Disease (GERD) Therapeutics market for 2018-2023.

Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition where stomach contents come back up into the esophagus resulting in either symptoms or complications.
Patent expiry of blockbuster drugs prescribed for the treatment of acid reflux disorders is majorly attributable for the downfall of this market.
Over the next five years, LPI(LP Information) projects that Gastroesophageal Reflux Disease (GERD) Therapeutics will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares and growth opportunities of Gastroesophageal Reflux Disease (GERD) Therapeutics market by product type, application, key companies and key regions.

To calculate the market size, LP Information considers value generated from the sales of the following segments:

Segmentation by product type:

• Antacids
• Pro-kinetic agents
• Proton Pump Inhibitors (PPIs)

Segmentation by application:

• Heartburn
• Acid reflux disorders

We can also provide the customized separate regional or country-level reports, for the following regions:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Spain
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:

• AstraZeneca
• Eisai
• GSK
• Takeda
• Johnson & Johnson

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

• To study and analyze the global Gastroesophageal Reflux Disease (GERD) Therapeutics market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
• To understand the structure of Gastroesophageal Reflux Disease (GERD) Therapeutics market by identifying its various subsegments.
• Focuses on the key global Gastroesophageal Reflux Disease (GERD) Therapeutics players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Gastroesophageal Reflux Disease (GERD) Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the size of Gastroesophageal Reflux Disease (GERD) Therapeutics submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size 2013-2023
  2.1.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size CAGR by Region
2.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Segment by Type
  2.2.1 Antacids
  2.2.2 Pro-kinetic agents
  2.2.3 H2 Receptor Blockers
  2.2.4 Proton Pump Inhibitors (PPIs)
2.3 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Type
  2.3.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Market Share by Type (2013-2018)
  2.3.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Growth Rate by Type (2013-2018)
2.4 Gastroesophageal Reflux Disease (GERD) Therapeutics Segment by Application
  2.4.1 Heartburn
  2.4.2 Acid reflux disorders
2.5 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Application
  2.5.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Market Share by Application (2013-2018)
  2.5.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Growth Rate by Application (2013-2018)

3 GLOBAL GASTROESOPHAGEAL REFLUX DISEASE (GERD) THERAPEUTICS BY PLAYERS

3.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Market Share by Players
  3.1.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Players (2016-2018)
  3.1.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Market Share by Players (2016-2018)
3.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 GASTROESOPHAGEAL REFLUX DISEASE (GERD) THERAPEUTICS BY REGIONS

4.1 Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Regions
4.2 Americas Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Growth
4.3 APAC Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Growth
4.4 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Growth
4.5 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Growth

5 AMERICAS

5.1 Americas Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Countries
5.2 Americas Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Type
5.3 Americas Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Countries
6.2 APAC Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Type
6.3 APAC Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics by Countries
7.2 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Type
7.3 Europe Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics by Countries
8.2 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Type
8.3 Middle East & Africa Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 GLOBAL GASTROESOPHAGEAL REFLUX DISEASE (GERD) THERAPEUTICS MARKET FORECAST

10.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size Forecast (2018-2023)
10.2 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Forecast by Regions
  10.2.1 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Forecast by Regions (2018-2023)
  10.2.2 Americas Market Forecast
  10.2.3 APAC Market Forecast
  10.2.4 Europe Market Forecast
  10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
  10.3.1 United States Market Forecast
  10.3.2 Canada Market Forecast
  10.3.3 Mexico Market Forecast
  10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
  10.4.1 China Market Forecast
  10.4.2 Japan Market Forecast
  10.4.3 Korea Market Forecast
  10.4.4 Southeast Asia Market Forecast
  10.4.5 India Market Forecast
  10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
  10.5.1 Germany Market Forecast
  10.5.2 France Market Forecast
  10.5.3 UK Market Forecast
  10.5.4 Italy Market Forecast
  10.5.5 Russia Market Forecast
  10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
  10.6.1 Egypt Market Forecast
  10.6.2 South Africa Market Forecast
  10.6.3 Israel Market Forecast
  10.6.4 Turkey Market Forecast
  10.6.5 GCC Countries Market Forecast
10.7 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Forecast by Type
10.8 Global Gastroesophageal Reflux Disease (GERD) Therapeutics Forecast by Application

11 KEY PLAYERS ANALYSIS

11.1 AstraZeneca
  11.1.1 Company Details
  11.1.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Product Offered
  11.1.3 AstraZeneca Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2016-2018)
  11.1.4 Main Business Overview
  11.1.5 AstraZeneca News
11.2 Eisai
  11.2.1 Company Details
  11.2.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Product Offered
  11.2.3 Eisai Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2016-2018)
  11.2.4 Main Business Overview
  11.2.5 Eisai News
11.3 GSK
  11.3.1 Company Details
  11.3.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Product Offered
  11.3.3 GSK Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2016-2018)
  11.3.4 Main Business Overview
  11.3.5 GSK News
11.4 Takeda
  11.4.1 Company Details
  11.4.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Product Offered
  11.4.3 Takeda Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2016-2018)
  11.4.4 Main Business Overview
  11.4.5 Takeda News
11.5 Johnson & Johnson
  11.5.1 Company Details
  11.5.2 Gastroesophageal Reflux Disease (GERD) Therapeutics Product Offered
  11.5.3 Johnson & Johnson Gastroesophageal Reflux Disease (GERD) Therapeutics Revenue, Gross Margin and Market Share (2016-2018)
  11.5.4 Main Business Overview
  11.5.5 Johnson & Johnson News

...

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Table Product Specifications of Gastroesophageal Reflux Disease (GERD) Therapeutics
Figure Gastroesophageal Reflux Disease (GERD) Therapeutics Report Years Considered
Figure Market Research Method